Servier Polska
Servier Polska is a Warsaw-based pharmaceutical subsidiary of the French Servier Group, developing, manufacturing, and supplying prescription medicines in cardiometabolism, oncology, and neurology, with the ANPHARM facility producing over 5 billion tablets annually for Polish patients and export to 18 EU countries.
- Company typePrivate
- Founded1992
- HeadquartersWarsaw, Poland
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Servier Polska does
Servier Polska Sp. z o.o. is the Polish subsidiary of LES LABORATOIRES SERVIER, a French international pharmaceutical company governed by a non-profit foundation (Fondation de Maison Servier). Founded in Poland in 1992 and headquartered in Warsaw at ul. Burakowska 14, the company is registered with KRS 0000139202 and NIP 526-030-28-87. It operates in three therapeutic areas — cardiometabolism, oncology, and neurology — with particular leadership in hypertension and venous disease treatment. The subsidiary holds the ANPHARM pharmaceutical manufacturing facility in Warsaw, acquired by the parent in 1997 and the first company in Poland to receive GMP certification (2003), producing over 5 billion tablets and 50 million packages annually as the 5th largest Servier production facility globally.
The company's core products include prescription branded and generic medications in cardiovascular, oncology (notably vorasidenib, the first molecularly targeted therapy for grade 2 glioma with IDH mutation, approved by the European Commission in September 2025), and neurology therapeutic areas. It operates mobile health applications (Angina Control, MyBP Control, MemoCards) for patient monitoring and medical education, and runs long-running national health awareness campaigns including Servier dla Serca (since 2003), Forum Przeciw Depresji (since 2007), and Wyłącz Raka (since 2017), with associated journalism awards (Kryształowe Pióra) and oncology research grants (Servier CARE). The company partners with all five major Polish medical societies (Cardiology, Hypertension, Oncology, Psychiatry, Diabetology) and the International Society of Hypertension / European Society of Cardiology.
The business model is B2B2C via pharmaceutical distribution: products are sold through pharmacy networks (including the FarmaProm platform) to patients via prescription, with pricing determined by market conditions and regulatory frameworks. ANPHARM produces APIs and finished dosage forms, with 63% of production exported to 18 EU countries and 98% of active substances sourced from EU manufacturing (primarily Bolbec, France). The company also generates commercial value through public health initiatives that build brand equity and physician engagement. Headcount is 501-1000 employees across Poland, while the parent Servier Group employs approximately 20,000 globally and reports €5.9 billion in revenue for FY 2023-2024 across approximately 140 countries. The foundation-governed ownership structure allows full profit reinvestment into R&D (over 20% of original drug sales) and long-term capital expenditure rather than shareholder returns.
Servier Polska firmographics
Firmographics- Name
- Servier Polska
- Legal name
- Servier Polska Sp. z o.o.
- Website
- https://www.servier.pl
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Servier Polska is a Warsaw-based pharmaceutical subsidiary of the French Servier Group, developing, manufacturing, and supplying prescription medicines in cardiometabolism, oncology, and neurology, with the ANPHARM facility producing over 5 billion tablets annually for Polish patients and export to 18 EU countries.
- Ownership category
- akta.pro rank
Servier Polska industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Servier Polska is headquartered
LocationHeadquarters
- HQ city
- Warsaw
- HQ country
- Poland
- HQ region
- Europe
Offices2 records
Markets served
Servier Polska business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Prescription Pharmaceuticals: Sale of branded prescription medications primarily in cardiovascular (cardiometabolism), oncology, and neurology therapeutic areas. Products include original branded drugs and generic medications.
- Oncology Drugs: Specialized oncology medications including IDH inhibitors for glioma treatment. Servier invests approximately 70% of R&D budget in oncology.
- Generic Medications: Servier offers a wide range of generic medications under recognized brands, particularly in Central-Eastern Europe and Brazil, to ensure broad access to affordable healthcare.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Pharmaceutical products - prescription-based pricing |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels9 records
Servier Polska product offering
Product offeringCore offering
Servier Polska develops, manufactures and supplies branded prescription pharmaceutical products across three core therapeutic areas: cardiometabolism (hypertension, cardiovascular disease, diabetes), oncology (including IDH-mutation targeted therapies such as vorasidenib for glioma), and neurology (depression). The company operates the ANPHARM manufacturing facility in Warsaw producing over 5 billion tablets annually, and supplements its pharmaceutical portfolio with patient-facing mobile health applications and nationwide disease prevention campaigns.
Product overview
Servier Polska is a pharmaceutical company operating as part of the international Servier Group. The company offers a portfolio of prescription pharmaceutical products primarily in three therapeutic areas: cardiometabolism, oncology, and neurology. Key products include cardiovascular and oncology medicines, along with mobile health applications (Angina Control, MyBP Control, MemoCards) for patient monitoring and medical education. The company operates a manufacturing facility (Anpharm) in Warsaw producing over 5 billion tablets annually. Servier Polska also runs public health initiatives including the Servier dla Serca campaign (since 2003), Forum Przeciw Depresji (since 2007), and Servier-Wyłącz Raka cancer prevention campaign (since 2017), as well as journalism awards (Kryształowe Pióra) and oncology research grants (Servier-CARE). The most recent pharmaceutical breakthrough is vorasidenib, the first molecularly targeted therapy for glioma with IDH mutation.
Differentiator
Problem solved
Functional benefit
Brands
- Anpharm: Pharmaceutical manufacturing facility located in Warsaw, part of Servier Group network since 1997
- Servier dla Serca
- Forum Przeciw Depresji
- Servier - Wyłącz Raka
- Kryształowe Pióra
Products and services
- Prescription Medicines (Leki na receptę) Pharmaceutical products available by prescription for cardiometabolic, oncological, and neurological conditions, sold through Polish pharmacy networks for patients prescribed by physicians.
- Vorasidenib (Worasydenib) First molecularly targeted therapy for adult and pediatric (12+ years, 40+ kg) patients with grade 2 glioma with IDH1 or IDH2 mutation after surgery. Indicated for a rare oncology indication and recognized with the Prix Galien 2025 award for Best Innovative Drug for Rare/Orphan Diseases.
- Angina Control (Dławica pod kontrolą) Mobile application for angina patients to monitor angina attacks, track circumstances, and record nitroglycerin usage. Provides weekly, monthly, and annual reports that can be shared with physicians. Available in Polish on iOS and Android.
- MyBP Control Mobile application for hypertensive patients to monitor blood pressure, track medication intake, and maintain a doctor appointment calendar. Features gamification with a 'tree growing' mechanic and enables data sharing with physicians. Available in Polish on iOS and Android.
- MemoCards Mobile flashcard application for medical professionals available on Android and iOS platforms, supporting medical education and continuing professional development.
- Generic Medications (Leki generyczne) Wide range of generic medications sold under recognized brands in Central-Eastern Europe (including Poland) and Brazil to ensure broad, affordable access to essential therapies across Servier's therapeutic areas.
Quantifiable outcome
- 50 million packages produced annually at Polish facility
- +3 more outcomes
Companies that use Servier Polska
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Servier Polska technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Servier Polska partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered minor and core.
- European Society of CardiologyminorEuropean partnership for Angina Awareness Initiative promoting knowledge about coronary artery disease symptoms and treatment.
- Polskie Towarzystwo Kardiologiczne (Polish Cardiological Society)coreLong-standing partnership for cardiovascular disease awareness campaigns including Servier dla Serca. Provides scientific patronage for health screening programs and educational initiatives.
- Polskie Towarzystwo Nadciśnienia Tętniczego (Polish Hypertension Society)coreProfessional medical society partnership for hypertension awareness campaigns and the Misja 50/30 program targeting 50% blood pressure control rate by 2030.
- Polskie Towarzystwo Onkologiczne (Polish Oncological Society)corePartnership for oncology awareness and prevention campaigns including Wyłącz Raka. Jointly organizes Servier CARE oncology grants competition.
- Polskie Towarzystwo Psychiatryczne (Polish Psychiatric Society)corePartnership for depression awareness campaign Forum Przeciw Depresji running since 2007.
- Polskie Towarzystwo Diabetologiczne (Polish Diabetological Society)corePartnership for diabetes education and awareness campaigns.
- Warsaw Health Innovation HubcorePartnership under which Servier CARE oncology grant competition is organized. Facilitates collaboration between pharmaceutical industry and medical research sector.
- Agencja Badań Medycznych (Medical Research Agency)minorCollaboration supporting medical research initiatives and oncology grant program.
- Dziennikarski Klub Promocji Zdrowia (Journalistic Health Promotion Club)coreLong-standing partner for Kryształowe Pióra journalism competition since 2006, promoting health journalism on civilizational diseases.
- FarmaPromcorePharmaceutical distribution platform enabling pharmacies to order Servier products. Products distributed through pharmacy network across Poland.
- Alivia Fundacja OnkologicznaminorPatient organization partner for Wyłącz Raka cancer prevention campaign.
- Fundacja MY PACJENCIminorPatient foundation partner for cancer prevention and patient education initiatives.
- Instytut Praw Pacjenta i Edukacji ZdrowotnejminorPatient rights and health education institute partner for Servier dla Serca and cancer prevention campaigns.
- Ogólnopolskie Stowarzyszenie Pacjentów ze Schorzeniami Serca i Naczyń 'EcoSerce'minorNational patient association partner for cardiovascular campaign Servier dla Serca.
- International Society of HypertensionminorInternational partnership for #bojatakmowie (#becauseisayso) campaign and May Measurement Month blood pressure awareness program.
Scale indicators16 records
Recent moves12 records
Expansion highlights10 records
Servier Polska competitors and assessment
Company assessmentDirect peers
- Polpharma: Poland's largest pharmaceutical manufacturer and a domestic champion in cardiology and generics. Directly comparable to Servier Polska as a Polish pharma incumbent with manufacturing scale, CEE distribution, and similar therapeutic breadth.
- Adamed Pharma: Polish pharmaceutical company with branded and generic portfolios spanning cardiology, neurology, and oncology. Comparable to Servier Polska in its mix of CEE-focused manufacturing, branded specialty products, and central-European GTM.
- KRKA: Slovenian pharma group with strong CEE presence in cardiology and generics, plus growing specialty pipeline. Closely comparable to Servier Polska in therapeutic focus (CV/metabolic), CEE export-driven manufacturing model, and branded-generic mix.
- Gedeon Richter: Hungarian pharmaceutical group with cardiology, CNS, and women's health portfolios plus biotech operations. Comparable to Servier Polska in CEE-centric branded-generic strategy and integrated manufacturing across the region.
- Zentiva: Pan-European generics and branded pharma headquartered in Prague with strong CEE footprint. Directly comparable to Servier Polska in CEE-focused branded-generic portfolio and cardiology/metabolic leadership.
Broad incumbents
- Sanofi: Global pharmaceutical major with strong cardiology (incl. historical Servier partnership), oncology, and rare disease franchises. Comparable to Servier Group at the parent level as a broad incumbent operating across all three of Servier Polska's therapeutic areas.
- Bayer Pharmaceuticals: Global pharma with cardiovascular (Xarelto), oncology (Stivarga — a glioma competitor), and specialty care. Comparable to Servier Polska as a broad incumbent with overlapping therapeutic areas, especially in oncology where Bayer competes head-to-head with vorasidenib.
- Novartis: Global oncology and cardiovascular leader with deep European footprint. Comparable to Servier Group as a broad incumbent; particularly relevant for Polish oncology launches and cardiovascular competition.
- AstraZeneca: Global pharma with leading oncology and cardiovascular/metabolic franchises (Tagrisso, Farxiga). Comparable to Servier Polska in overlapping therapeutic areas and growing CEE presence through targeted oncology launches.
Emerging players
- Lupin (CEE operations): India-headquartered global pharma expanding branded generics and specialty in CEE. Comparable to Servier Polska as an emerging player building branded-generic scale in Polish and CEE cardiometabolic channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Servier Polska social profiles
Digital presenceServier Polska compliance and trust
Trust signalCompliance4 records
Servier Polska financial estimates
Financial estimateRevenue estimate
Valuation estimate
Servier Polska leadership team
Management profileNumber of profiles
Profiles3 records
Servier Polska subsidiaries and ownership
Company hierarchySubsidiaries1 record
Servier Polska funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Servier Polska M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Servier Polska
What does Servier Polska do?
Servier Polska develops, manufactures and supplies branded prescription pharmaceutical products across three core therapeutic areas: cardiometabolism (hypertension, cardiovascular disease, diabetes), oncology (including IDH-mutation targeted therapies such as vorasidenib for glioma), and neurology (depression). The company operates the ANPHARM manufacturing facility in Warsaw producing over 5 billion tablets annually, and supplements its pharmaceutical portfolio with patient-facing mobile health applications and nationwide disease prevention campaigns.
Is Servier Polska a public or private company?
Servier Polska is a private company. It is classified as corporate owned and is currently operating.
When was Servier Polska founded?
Servier Polska was founded in 1992. It employs 501 to 1,000 people.
Where is Servier Polska based?
Servier Polska is headquartered in Warsaw, Poland, in the Europe region.
How does Servier Polska make money?
Three revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are oncology Drugs and generic Medications.
Who are Servier Polska's main competitors?
Direct peers on record are Polpharma, Adamed Pharma, KRKA, Gedeon Richter and Zentiva. Broad incumbents are Sanofi, Bayer Pharmaceuticals, Novartis and AstraZeneca. Lupin (CEE operations) is listed as an emerging player.
Does Servier Polska have an API?
No public API is recorded for Servier Polska.
What industry is Servier Polska in?
Servier Polska's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.